


Amendments to the Claims

This Listing of Claims will replace all prior versions, and listings, of claims in the specification:

Listing of Claims:

1-11. (Canceled)

12. (Currently Amended) The A compound according to claim 7 of the formula (Ib):



wherein

Y is CH:

W is $-NR_5C(O)R_6$, $-NR_5C(O)OR_6$, $-NR_5C(O)NR_6R_7$, $-NR_5C(S)NR_6R_7$, $-NR_5S(O)_2R_6$, $-NR_5R_8$, $-C(O)NR_6R_7$, or $-OC(O)NR_6R_7$ in which

R_5 and R_7 are independently hydrogen or methyl;


R_6 is C_{1-4} alkyl, phenyl, naphthyl, thienyl, furanyl, pyrrolyl, morpholinyl, piperidinyl, piperazinyl, pyridinyl, benzothiophenyl, benzodioxoyl or cycloalkyl each of which may be optionally substituted by one to four substituents such as independently selected from the group consisting of halo, hydroxy, alkoxy, alkanoyl, alkanoyloxy, optionally substituted amino, thiol, alkylthio, nitro, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, alkylthiono, alkyl, arylsulfonyl, sulfonamido and heterocycloyl;

R_8 is a phenyl, naphthyl, thienyl, furanyl, pyrrolyl, morpholinyl, piperidinyl, piperazinyl, pyridinyl, benzothiophenyl, benzodioxoyl or a cycloalkyl, which may be optionally substituted with halogen, C_{1-4} alkoxy, amino, nitro or cyano; and

R_{13} and R_{14} are independently hydrogen, hydroxy or methyl;

or a pharmaceutically acceptable salt thereof.

13. (Currently Amended) The A compound according to claim 7 of the formula (lc):



wherein

R₂ is hydrogen, halo or C₁₋₄alkoxy;

Y is CH;

R₁₃ and R₁₄ are independently hydrogen, hydroxy or methyl;

R₁₅ is hydrogen, -NR₅C(O)R₆, -NR₅C(O)OR₈, -NR₅C(O)NR₆R₇, -NR₅C(S)NR₆R₇, -NR₅S(O)₂R₈, -NR₅R₆, -C(O)NR₆R₇, -OR₉ or -OC(O)NR₆R₇ in which


R₅ and R₇ are independently hydrogen or methyl;

R₆ is C₁₋₄ alkyl, phenyl, naphthyl, thienyl, furanyl, pyrrolyl, morpholinyl, piperidinyl, piperazinyl, pyridinyl, benzothiophenyl, benzodioxoyl or cycloalkyl each of which may be optionally substituted by one to four substituents such as independently selected from the group consisting of halo, hydroxy, alkoxy, alkanoyl, alkanoyloxy, optionally substituted amino, thiol, alkylthio, nitro, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, alkylthiono, alkyl, arylsulfonyl, sulfonamido and heterocycloyl; and

R₈ and R₉ are each, independently, a phenyl, naphthyl, thienyl, furanyl, pyrrolyl, morpholinyl, piperidinyl, piperazinyl, pyridinyl, benzothiophenyl, benzodioxoyl or a cycloalkyl, which may be optionally substituted with halogen, C₁₋₄ alkoxyl, amino, nitro or cyano; or a pharmaceutically acceptable salt thereof.

14-17. (Canceled).

18. (Currently Amended) The A compound having the according to formula (lh):



wherein

R₁ and R₂ are independently hydrogen, halo, amino, C₁₋₄ alkylamino, C₁₋₄ alkyl or C₁₋₄ alkoxy; or

R₁ and R₂ combined together form an optionally substituted phenyl ring;

W is $-NR_5C(O)R_6$, $NR_5C(O)OR_6$, $-NR_5C(O)NR_6R_7$, $-NR_5C(S)NR_6R_7$, $-NR_5S(O)_2R_6$, $-NR_5R_6$, $-C(O)NR_6R_7$, or $-OC(O)NR_6R_7$ in which

R_5 and R_7 are independently hydrogen or methyl; ~~or~~

R_6 is C_{1-4} alkyl, phenyl, naphthyl, thienyl, furanyl, pyrrolyl, morpholinyl, piperidinyl, piperazinyl, pyridinyl, benzothiophenyl, benzodioxoyl or cycloalkyl optionally substituted by one to four substituents ~~such as~~ independently selected from the group consisting of halo, hydroxy, alkoxy, alkanoyl, alkanoyloxy, optionally substituted amino, thiol, alkylthio, nitro, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, alkylthiono, alkyl, arylsulfonyl, sulfonamido and heterocycloyl;

R_8 and R_9 are each, independently, a phenyl, naphthyl, thienyl, furanyl, pyrrolyl, morpholinyl, piperidinyl, piperazinyl, pyridinyl, benzothiophenyl, benzodioxoyl or a cycloalkyl, which may be optionally substituted with halogen, C_{1-4} alkoxy, amino, nitro or cyano; or

W and R_1 combined together with the carbon atoms to which they are attached form a 6-membered phenyl ring optionally substituted with alkyl, alkoxy, aryl, heteroaryl, halo, $-NR_5Z$, $-C(O)NR_6R_7$, $-OR_9$ or $-OC(O)NR_6R_7$ in which

Z is $-C(O)R_6$, $-C(O)OR_6$, $-C(O)NR_6R_7$, $-C(S)NR_6R_7$, $-S(O)_2R_6$, or $-R_8$;

R_{13} and R_{14} are independently hydrogen, hydroxy or methyl;

X is CH; and

Y is CH;

or a pharmaceutically acceptable salt thereof.

19. (Currently Amended) The compound according to claim 18 wherein

R_1 is hydrogen;

R_2 is hydrogen, chloro, methoxy, ethoxy, propoxy amino or C_{1-4} alkylamino;

W is $-NR_5C(O)R_6$, $-NR_5C(O)OR_6$, $-NR_5C(O)NR_6R_7$, $-NR_5C(S)NR_6R_7$, $-NR_5S(O)_2R_6$, $-NR_5R_6$, $-C(O)NR_6R_7$, or $-OC(C)NR_6R_7$ in which

R_5 and R_7 are independently hydrogen or methyl;

R_6 is C_{1-4} alkyl, phenyl, naphthyl, thienyl, furanyl, pyrrolyl, morpholinyl, piperidinyl, piperazinyl, pyridinyl, benzothiophenyl, benzodioxoyl or cycloalkyl each of which may be optionally substituted by one to four substituents ~~such as~~ independently selected from the group consisting of halo, hydroxy, alkoxy, alkanoyl, alkanoyloxy, optionally substituted amino, thiol, alkylthio, nitro, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, alkylthiono, alkyl, arylsulfonyl, sulfonamido and heterocycloyl;

R_8 is a phenyl, naphthyl, thienyl, furanyl, pyrrolyl, morpholinyl, piperidinyl, piperazinyl, pyridinyl, benzothiophenyl, benzodioxoyl or a cycloalkyl, which may be optionally substituted with halogen, C_{1-4} alkoxy, amino, nitro or cyano;

~~or~~

X is CH;

Y is CH; and

R₁₃ and R₁₄ are independently hydrogen, hydroxy or methyl;
or a pharmaceutically acceptable salt thereof.

20. (Currently Amended) The compound according to claim 18 wherein

R₁ is methyl, methoxy or optionally substituted amino;

R₂ is hydrogen;

W is -NR₅C(O)R₆, -NR₅C(O)OR₆, -NR₅C(O)NR₆R₇, -NR₅C(S)NR₆R₇, -NR₅S(O)₂R₆,
-NR₅R₈, -C(O)NR₆R₇, or -OC(O)NR₆R₇ in which

R₅ and R₇ are independently hydrogen or methyl;

R₆ is C₁₋₄alkyl, phenyl, naphthyl, thienyl, furanyl, pyrrolyl, morpholinyl, piperidinyl, piperazinyl, pyridinyl, benzothiophenyl, benzodioxoyl or cycloalkyl each of which may be optionally substituted by one to four substituents such as independently selected from the group consisting of halo, hydroxy, alkoxy, alkanoyl, alkanoyloxy, optionally substituted amino, thiol, alkylthio, nitro, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, alkylthiono, alkyl, arylsulfonyl, sulfonamido and heterocycloyl;

R₈ is a phenyl, naphthyl, thienyl, furanyl, pyrrolyl, morpholinyl, piperidinyl, piperazinyl, pyridinyl, benzothiophenyl, benzodioxoyl or a cycloalkyl, which may be optionally substituted with halogen, C₁₋₄ alkoxy, amino, nitro or cyano;

or

X is CH;


Y is CH; and

R₁₃ and R₁₄ are independently hydrogen, hydroxy or methyl ~~optionally substituted lower~~
alkyl;

or a pharmaceutically acceptable salt thereof.

21. (Canceled).

22. (Currently Amended) The compound according to claim 18 ~~of the~~ represented by
formula (II):



wherein

W is -NR₅C(O)R₆, -NR₅C(O)OR₆, -NR₅C(O)NR₆R₇, -NR₅C(S)NR₆R₇, -NR₅S(O)₂R₆,
-NR₅R₈, -C(O)NR₆R₇, -OR₉ or -OC(O)NR₆R₇ in which

R₅ and R₇ are independently hydrogen or methyl;

R₅ is C₁₋₄alkyl, phenyl, naphthyl, thienyl, furanyl, pyrrolyl, morpholinyl, piperidinyl, piperazinyl, pyridinyl, benzothiophenyl, benzodioxoyl or cycloalkyl each of which may be optionally substituted by one to four substituents such as independently selected from the group consisting of halo, hydroxy, alkoxy, alkanoyl, alkanoyloxy, optionally substituted amino, thiol, alkylthio, nitro, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, alkylthiono, alkyl, arylsulfonyl, sulfonamido and heterocycloyl;

R₆ is a phenyl, naphthyl, thienyl, furanyl, pyrrolyl, morpholinyl, piperidinyl, piperazinyl, pyridinyl, benzothiophenyl, benzodioxoyl or a cycloalkyl, which may be optionally substituted with halogen, C₁₋₄ alkoxyl, amino, nitro or cyano;

or

Y is CH; and

R₁₃ and R₁₄ are independently hydrogen, hydroxy or methyl;
or a pharmaceutically acceptable salt thereof.

23-24. (Canceled)

25. (Withdrawn, Currently Amended) A method for the inhibition of 11 β -hydroxysteroid dehydrogenase type 1 (11 β -HSD1) oxoreductase activity in mammals, which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim [[1]] 18, or a pharmaceutically acceptable salt thereof.

26. (Withdrawn, Currently Amended) A method to control glucocorticoid concentration in mammals which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim [[1]] 18, or a pharmaceutically acceptable salt thereof.

27. (Withdrawn) A method according to claim 26, which comprises lowering intracellular and hepatic glucocorticoid concentrations, increasing insulin sensitivity in the adipose tissue and in the muscle, reducing lipolysis and free fatty acid production in the adipose tissue, and inhibiting hepatic gluconeogenesis.

28. (Withdrawn, Currently Amended) A method for the treatment of conditions associated with 11 β -HSD1 oxoreductase activity in mammals which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim [[1]] 18, or a pharmaceutically acceptable salt thereof.

29. (Withdrawn, Currently Amended) A method for the treatment of glucocorticoid associated disorders in mammals which method comprises administering to a mammal in need

thereof a ~~therapeutically~~ therapeutically effective amount of a compound of claim ~~[[1]]~~ 18, or a pharmaceutically acceptable salt thereof.

30. (Withdrawn, Currently Amended) A method ~~according to claim 29, for the treatment of~~ glucocorticoid associated disorders in mammals which comprises administering a compound of claim ~~[[1]]~~ 18, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of insulin, insulin derivative or mimetic, insulin secretagogue, insulinotropic sulfonylurea receptor ligand, insulin sensitizer, biguanide, alpha-glucosidase inhibitor, GLP-1, GLP-1 analog or mimetic, DPP-IV inhibitor, hypolipidemic agent, anti-obesity agent, cholestyramine, fibrate, nicotinic acid, or aspirin.

31. (Withdrawn, Currently Amended) A method for the treatment of impaired glucose tolerance in Type 2 diabetes which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim ~~[[1]]~~ 18, or a pharmaceutically acceptable salt thereof.

32. (Withdrawn, Currently Amended) A method for the treatment of Syndrome-X, dyslipidemia, hypertension and central obesity which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim ~~[[1]]~~ 18, or a pharmaceutically acceptable salt thereof.

33. (Currently Amended) A pharmaceutical composition, comprising:
the a compound of claim ~~[[7]]~~ 12, or a pharmaceutically acceptable salt thereof, in a therapeutically effective amount, in combination with one or more pharmaceutically acceptable carriers.

34-39. (Canceled)

40. (Currently Amended) A pharmaceutical composition, comprising:
the a compound of claim 18, or a pharmaceutically acceptable salt thereof, in a therapeutically effective amount, in combination with one or more pharmaceutically acceptable carriers.

41. (New) A pharmaceutical composition, comprising:
a compound of claim 13, or a pharmaceutically acceptable salt thereof, in a therapeutically effective amount, in combination with one or more pharmaceutically acceptable carriers.

42. (Withdrawn, New) A method for the inhibition of 11 β -hydroxysteroid dehydrogenase type 1 (11 β -HSD1) oxoreductase activity in mammals, which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 12, or a pharmaceutically acceptable salt thereof.
43. (Withdrawn, New) A method to control glucocorticoid concentration in mammals which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 12, or a pharmaceutically acceptable salt thereof.
44. (Withdrawn, New) A method according to claim 43, which comprises lowering intracellular and hepatic glucocorticoid concentrations, increasing insulin sensitivity in the adipose tissue and in the muscle, reducing lipolysis and free fatty acid production in the adipose tissue, and inhibiting hepatic gluconeogenesis.
45. (Withdrawn, New) A method for the treatment of conditions associated with 11 β -HSD1 oxoreductase activity in mammals which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 12, or a pharmaceutically acceptable salt thereof.
46. (Withdrawn, New) A method for the treatment of glucocorticoid associated disorders in mammals which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 12, or a pharmaceutically acceptable salt thereof.
47. (Withdrawn, New) A method for the treatment of glucocorticoid associated disorders in mammals which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 12, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of insulin, insulin derivative or mimetic, insulin secretagogue, insulinotropic sulfonylurea receptor ligand, insulin sensitizer, biguanide, alpha-glucosidase inhibitor, GLP-1, GLP-1 analog or mimetic, DPP-IV inhibitor, hypolipidemic agent, anti-obesity agent, cholestyramine, fibrate, nicotinic acid, or aspirin.
48. (Withdrawn, New) A method for the treatment of impaired glucose tolerance in Type 2 diabetes which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 12, or a pharmaceutically acceptable salt thereof.

49. (Withdrawn, New) A method for the treatment of Syndrome-X, dyslipidemia, hypertension and central obesity which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 12, or a pharmaceutically acceptable salt thereof.
50. (Withdrawn, New) A method for the inhibition of 11 β -hydroxysteroid dehydrogenase type 1 (11 β -HSD1) oxoreductase activity in mammals, which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 13, or a pharmaceutically acceptable salt thereof.
51. (Withdrawn, New) A method to control glucocorticoid concentration in mammals which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 13, or a pharmaceutically acceptable salt thereof.
52. (Withdrawn, New) A method according to claim 51, which comprises lowering intracellular and hepatic glucocorticoid concentrations, increasing insulin sensitivity in the adipose tissue and in the muscle, reducing lipolysis and free fatty acid production in the adipose tissue, and inhibiting hepatic gluconeogenesis.
53. (Withdrawn, New) A method for the treatment of conditions associated with 11 β -HSD1 oxoreductase activity in mammals which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 13, or a pharmaceutically acceptable salt thereof.
54. (Withdrawn, New) A method for the treatment of glucocorticoid associated disorders in mammals which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 13, or a pharmaceutically acceptable salt thereof.
55. (Withdrawn, New) A method for the treatment of glucocorticoid associated disorders in mammals which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 13, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of insulin, insulin derivative or mimetic, insulin secretagogue, insulinotropic sulfonylurea receptor ligand, insulin sensitizer, biguanide, alpha-glucosidase inhibitor, GLP-1, GLP-1 analog or mimetic, DPP-IV inhibitor, hypolipidemic agent, anti-obesity agent, cholestyramine, fibrate, nicotinic acid, or aspirin.

56. (Withdrawn, New) A method for the treatment of impaired glucose tolerance in Type 2 diabetes which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 13, or a pharmaceutically acceptable salt thereof.

57. (Withdrawn, New) A method for the treatment of Syndrome-X, dyslipidemia, hypertension and central obesity which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 13, or a pharmaceutically acceptable salt thereof.